The estimated Net Worth of Celeste Ferber is at least $3.85 Milion dollars as of 15 September 2020. Celeste Ferber owns over 2,396 units of Aduro BioTech stock worth over $3,810,670 and over the last 6 years Celeste sold ADRO stock worth over $36,162.
Sign up
Celeste Ferber ADRO stock SEC Form 4 insiders trading
Celeste has made over 5 trades of the Aduro BioTech stock since 2019, according to the Form 4 filled with the SEC. Most recently Celeste sold 2,396 units of ADRO stock worth $5,726 on 15 September 2020.
The largest trade Celeste's ever made was selling 7,951 units of Aduro BioTech stock on 7 August 2020 worth over $20,275. On average, Celeste trades about 1,906 units every 61 days since 2019. As of 15 September 2020 Celeste still owns at least 38,687 units of Aduro BioTech stock.
You can see the complete history of Celeste Ferber stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Celeste Ferber's mailing address?
Celeste's mailing address filed with the SEC is C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY, CA, 94710.
Insiders trading at Aduro BioTech
Over the last 10 years, insiders at Aduro BioTech have traded over $5,295,750 worth of Aduro BioTech stock and bought 614,134 units worth $10,440,278 . The most active insiders traders include William Mariner Greenman, Stephen T Isaacs oraz Thomas W. Dubensky. On average, Aduro BioTech executives and independent directors trade stock every 11 days with the average trade being worth of $2,189,064. The most recent stock trade was executed by Stephen T Isaacs on 15 September 2020, trading 32,481 units of ADRO stock currently worth $77,630.
What does Aduro BioTech do?
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
What does Aduro BioTech's logo look like?
Complete history of Celeste Ferber stock trades at Aduro BioTech
Aduro BioTech executives and stock owners
Aduro BioTech executives and other stock owners filed with the SEC include:
-
William Greenman,
Independent Director -
Ross Haghighat,
Independent Director -
Eric Bjerkholt,
Chief Financial Officer -
Noopur Liffick,
IR Contact Officer -
Dolca Thomas,
Director -
Michelle Griffin,
Director -
Jerel Davis,
Director -
Srinivas Akkaraju,
Director -
Alan Glicklich,
Chief Medical Officer -
Tom Frohlich,
Chief Business Officer -
Eric Dobmeier,
President, Chief Executive Officer, Director -
Thomas W. Dubensky,
Chief Scientific Officer -
Gregory W Schafer,
Chief Operating Officer -
Natalie Sacks,
Chief Medical Officer -
Frank Mccormick,
Director -
Gerald Chan,
Director -
Stephen T Isaacs,
President and CEO -
Stephanie Monaghan O Brien,
Director -
Stephen A Sherwin,
Director -
Dirk G. Brockstedt,
Sr. VP of Research and Dev. -
Frank Karbe,
Director -
Elsas Andrea Van,
Chief Scientific Officer -
David Henry Mack,
Director -
Celeste Ferber,
SVP, GC and Secretary -
Dimitry Sa Nuyten,
Chief Medical Officer -
Jennifer Lew,
Sr. Vice President of Finance -
Venture (Vi) Investments Lt...,
10% owner -
John E. And Lois A. Rogers,
10% owner -
Keen Ltd Ultimate,
10% owner -
Blaine Templeman,
Chief Legal Officer -
James H Welch,
See Remarks -
William G Kachioff,
Interim CFO